Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity.
Obesity is a disease of increased fat mass resulting from an imbalance in the intake and expenditure of energy. Research has shown that genetic factors can influence this balance. When an individual’s genetic makeup is susceptible to an environment that promotes energy consumption over energy expenditure, this is known as polygenic obesity, or common obesity.1
Rare genetic disorders of obesity are different. Sometimes, a variant in the genes can cause a disorder. More specifically, rare genetic disorders of obesity occur in the melanocortin 4 (MC4) pathway, which regulates weight by increasing energy expenditure and reducing appetite.
MC4 pathway deficiencies can result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to unrelenting hunger, known as hyperphagia, and to severe, early-onset obesity. The MC4 pathway is proving to be a compelling target for treating these rare genetic disorders because of its critical role in regulating appetite and weight.